Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2026-02-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange (HKEX). This is a standard regulatory filing required by the HKEX Listing Rules (specifically Rule 13.25A) to report monthly movements in securities, share capital, and treasury shares. Since it does not fit into specific categories like 'Share Issue' (which would be a specific event) or 'Annual Report', and is a recurring regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2026-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Transaction in Own Shares' (which is for specific buybacks), it falls under the 'Regulatory Filings' category.
2026-01-07 English
UPDATES ON LICENSING TRANSACTION
Capital/Financing Update Classification · 95% confidence The document is an announcement from Lepu Biopharma Co., Ltd. regarding the fulfillment of conditions precedent for a previously announced licensing transaction and share purchase agreement. It provides detailed information about the royalty payment structure and the identities of the 'Excalipoint Series A Investors'. This type of disclosure, which details corporate transactions, financing, and investor structures, is classified as a capital or financing update.
2025-12-18 English
POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 18, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement titled 'POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING'. It details the attendance, the specific resolutions proposed, the voting results (for, against, abstain), and confirms that the resolutions were passed. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-12-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in their securities, including share capital, issued shares, and treasury shares. While it relates to share capital, it is a recurring regulatory filing rather than a specific 'Share Issue/Capital Change' (SHA) announcement for a single event, and it is not a report publication announcement. Given the specific nature of the HKEX monthly return, it falls under the 'Regulatory Filings' category as the most appropriate classification.
2025-12-04 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is the 'Articles of Association' for Lepu Biopharma Co., Ltd. This document outlines the company's internal governance, share structure, board responsibilities, and operational scope. In corporate reporting, the Articles of Association are a fundamental governance document that defines the company's legal framework and is typically categorized under Governance Information (CGR).
2025-12-02 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.